LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, has been named the recipient of the 2009 David M. Hume Award. He will accept his award tonight at an awards dinner during the National Kidney Foundation's annual Spring Clinical Meetings in Nashville, TN.
The David M. Hume Award was created in memory of one of the National Kidney Foundation's most distinguished members and is the highest honor awarded by the National Kidney Foundation. It is given to a distinguished scientist-clinician in the field of kidney and urologic diseases who exemplifies the ideals of scholarship and humanitarianism.
"We are very pleased to present this award to Dr. Pereira. His two decades of research has resulted in better designed policies in dialysis centers and organ transplantation and a better understanding of the transmission and course of hepatitis C in nephrology. His research has emphasized the importance of inflammation in chronic kidney disease and resulted in a greater focus on chronic kidney disease care," stated Bryan Becker, MD, President, National Kidney Foundation.
In addition to his position as President and CEO of AMAG Pharmaceuticals, Inc., Dr. Pereira is a nationally recognized expert on kidney disease and nephrology, is the editor of the widely read textbook Chronic Kidney Disease, Dialysis and Transplantation and has authored over 200 scientific papers. He is also a Professor of Medicine at Tufts University School of Medicine and at the Sackler School of Biomedical Sciences of Tufts University.
For more information, please visit the National Kidney Foundation website at: http://www.kidney.org/news/meetings/clinical/recognition/award_DavidMHume.cfm
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Feraheme(TM) (ferumoxytol injection) is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease.
About the National Kidney Foundation
The National Kidney Foundation is dedicated to preventing kidney and urinary tract diseases, improving the health and well-being of those affected by these diseases and increasing the availability of all organs for transplantation. For more information visit www.kidney.org
Source: AMAG Pharmaceuticals